Platelet Derived Growth Factor BB: A “Must-have” Therapeutic Target “Redivivus” in Ovarian Cancer

Cimpean, Anca Maria; Cobec, Ionut Marcel; Ceauşu, Raluca Amalia; Popescu, Roxana; Tudor, Anca; Raica, Marius

doi:10.21873/cgp.20014

Cited by 15 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, this is the first study of the expression of PDGF-BB in radiotherapy treated EC. PDGF-BB was previously reported to be significantly associated with many human tumors including colorectal cancer [10,11], pancreatic cancer [11][12][13], non-small cell lung cancer [14], renal cancer [15], ovarian cancer [16], liver carcer [17,18] and even osteosarcoma [19]. Current thinking is that overexpression of the PDGF family probably leads to a poor prognosis by modulating both hematopoiesis and tumor angiogenesis [20].…”

Section: Discussionmentioning

confidence: 99%

The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy

Dong

Zhang

et al. 2020

Aging

View full text Add to dashboard Cite

Radiotherapy is the major approach and is well tolerated in locally advanced esophageal squamous cell carcinoma (ESCC). And nowadays, no effective biological markers have been identified for predicting the prognosis of patients with ESCC. Platelet-derived growth factor (PDGF) is associated with a poor prognosis of various malignancies. The present study aimed to assess the effect of PDGF-BB on radiotherapeutic responses of ESCC and the underlying mechanisms of its roles in ESCC. Serum from 68 cases that received neoadjuvant or radical radiotherapy was obtained before and during radiotherapy. Gene expression analyses were validated by enzyme linked immunosorbent assay. The prognosis of patients with significantly reduced PDGF-BB was probably better than that of the others found in the progression-free survival and overall survival groups. Depletion of PDGFB significantly suppressed the proliferation, invasion and migration of cancer cells. Inhibiting PDGFB induced cellular apoptosis and promoted the sensitivity to ionizing radiation (IR). Furthermore, IR inhibited PDGF-BB-induced migration by blocking the PI3K/AKT pathway in ESCC cells. We found that the expression of PDGF-BB provided a possible model for predicting ESCC radiotherapy. It can also be used as a prognostic indicator for locally advanced ESCC that was treated by radiotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy

Dong

Zhang

et al. 2020

Aging

View full text Add to dashboard Cite

show abstract

“…Accumulating evidence indicates increased expression of 14-3-3beta in various types of solider tumors (3–10, 21). In 2018, Seo et al reported that 14-3-3beta negatively regulated the glioblastoma cells senescence via the ERK-SKP2-p27 pathway (7).…”

Section: Discussionmentioning

confidence: 99%

“…In this study, we retrospectively analyzed paraffin slices obtained from 70 DLBCL patients and 50 non-neoplastic lymph nodes (3–5, 8, 10, 12, 21). Immunohistochemical staining showed that 14-3-3beta gene expression was significantly decreased in DLBCL tissues ( P < 0.0001) compared to that in non-neoplastic lymph nodes.…”

Section: Discussionmentioning

confidence: 99%

Low Expression of 14-3-3beta Is Associated With Adverse Survival of Diffuse Large B-Cell Lymphoma Patients

Zhang

2019

Front. Med.

View full text Add to dashboard Cite

Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin's lymphoma in the world, is highly heterogeneous. Although current therapies have improved the clinical outcome, 30–40% of the patients are still not cured. Thus, novel treatment options such as targeted therapy is urgently needed. Accumulating evidence suggests that 14-3-3beta protein plays an important role in tumorigenesis and tumor progression. However, the specific roles of 14-3-3beta in DLBCL are still poorly understood. In this study, we retrospectively analyzed 120 archived wax blocks obtained from patients with DLBCL (n = 70) and non-neoplastic lymph nodes (n = 50). Immunohistochemical staining showed that 14-3-3beta gene expression was significantly decreased in DLBCL tissues (P < 0.001) compared to that in non-neoplastic lymph nodes. Low 14-3-3beta expression was significantly correlated with extra-nodal status (P = 0.026), serum LDH level (P = 0.023) and adverse survival of DLBCL patients. In survival analyses, low 14-3-3beta expression was significantly associated with adverse overall survival of the DLBCL patients (P = 0.003). Using the Kaplan-Meier analysis module of the R2 microarray analysis and visualization platform (http://r2.amc.nl), we also confirmed that low expression of 14-3-3beta gene had inferior overall survival in DLBCL patients. Based on our results, we conclude that low expression of 14-3-3beta is associated with adverse survival of diffuse large B-cell lymphoma patients, suggesting a novel prognostic marker and potential therapeutic target.

show abstract

“…Angiogenesis, hypoxia and inflammation can be identified on the cellular level (18). Excessive angiogenesis is mainly a feature of malignant development, but also an important component for other pathologic conditions (4,(19)(20)(21)(22)(23)(24)(25).…”

Section: Introductionmentioning

confidence: 99%

Ovarian cancer health politics in Romania and Germany: A comparative study

Cobec

Sas

Moatar³

et al. 2021

Exp Ther Med

View full text Add to dashboard Cite

Ovarian cancer is known to have a poor prognosis, being the 7th most common cancer type in women with regard to incidence and mortality worldwide. The present study underlines the importance of early diagnosis and prevention management of ovarian cancer. This study is a hospital-based case-control study that was conducted at the same time in two similar hospitals from different countries, Romania and Germany, over three years. The results showed that significant differences were identified for the two groups with regards to the age factor (P<0.001). A risk analysis was performed to determine whether the patients from Romania were exposed to a risk factor. The risk of developing deadly diseases was deemed much higher owing to insufficient protocols or informative programs in Romania. The medical information, early diagnosis and standardized therapy with optimum treatment based on health policy and health care systems, play a key role concerning the management and prognosis of ovarian cancer which are different from country to country.

show abstract

Platelet Derived Growth Factor BB: A “Must-have” Therapeutic Target “Redivivus” in Ovarian Cancer

Cited by 15 publications

References 26 publications

The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy

The expression of PDGF-BB predicts curative effect in locally advanced esophageal squamous cell carcinoma treated by radiotherapy

Low Expression of 14-3-3beta Is Associated With Adverse Survival of Diffuse Large B-Cell Lymphoma Patients

Ovarian cancer health politics in Romania and Germany: A comparative study

Contact Info

Product

Resources

About